Azenta, Inc. (AZTA) PT Lowered to $115 at Needham & Company

Needham & Company analyst David Saxon lowered the price target on Azenta, Inc. (NASDAQ: AZTA) to $115.00 (from $155.00) while maintaining a Buy rating.

The analyst commented, "AZTA’s F1Q22 revenue and EPS beat consensus and management provided F2Q22 revenue and EPS guidance that bracketed consensus. Strength was driven by SRS and GENEWIZ, which should continue into F2Q22 given tough comps for the Products category. We expect management to be active in M&A given the ~$2.4B in cash on the balance sheet. We believe AZTA has visibility into acclerating revenue growth all while seeing meaningful margin improvement, and we reiterate our Buy rating."

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• CVS Health (CVS) PT Raised to $110 at BofA Securities
• Definium Therapeutics Inc (DFTX) PT Raised to $52 at Leerink